Interview: Frans Labuschagne – Head of Pharma, Bayer South Africa
The head of pharma for Bayer Southern Africa reveals how South Africa plays a key role in Bayer’s African strategy, with more than 60 percent of the continent’s total sales,…
Address: South Wing, The Place, 1 Sandton Drive, Sandton, 2196
P O Box 784746, Sandton City, Sandton, 2146 ,South Africa
Tel: (+27-11) 783 0104
Web: http://www.drreddys.com/southafrica/
Dr. Reddy’s – South Africa operation is a wholly-owned subsidiary and one of the leading generics players in the country. With a dedicated field force it focuses on key therapeutic areas like Central Nervous System (CNS) and Primary Care.
The business performance in South Africa has been phenomenal in the last few years. The overall revenue as per FY10 has been at $9.4 million enlisting a 56% growth.
Its advantageous position is ensured through the presence of key contributors in its business model. The Research & Development capability helps the company ensure enhanced FTL Opportunities through non-infringing pdts and supports differentiation with products and competitors. Alongside, the in-house API manufacturing capabilities assures cost competitiveness in both private and tender based markets. The company’s Formulation capabilities and strong business development team ensures high-quality in-house product pipeline, shapes licensing strategy to maximize market share and enrich the product basket. All the more its committed filed force has also been promising in recent years while reaching to all segments of the market.
In the South Africa Generic market Dr. Reddy’s is ranked 18th in terms of Value and 20th in terms of volume (Source: IMS-SA IGMS, MAT, Nov. 2010).
Top-five products including Omez, Cifloc, Citraz, Amlate and DRL-Moxifloxacin contribute to over 50% of revenue.
Products cathegories:
Active Pharma Ingredients (API)
Custom Pharma Services (CPS)
Global Generics
New Chemical Entities (NCEs)
Differentiated Formulations
Biosimilars
The head of pharma for Bayer Southern Africa reveals how South Africa plays a key role in Bayer’s African strategy, with more than 60 percent of the continent’s total sales,…
The CEO of Pharma Dynamics explains why the company was the perfect match for Lupin, as the fastest growing, and largest independently owned acquirable pharmaceutical business in South Africa, why…
The chairman of PHARMISA reveals how pharmaceuticals has been designated as one of eight priority sectors of South African Government’s Industrial Policy Action Plan (IPAP), how South African life expectancy…
The CEO of Pierre Fabre for South Africa reveals how his focus has been on marketing the company brand locally, why the goal of the company is to develop business…
The EO of SAMED discusses recent regulations surrounding the medical device industry in South Africa, why South Africa remains the hub and the major gateway to Africa for medical devices…
The managing director of UTi Pharma reveals how UTi is no longer just an international forwarding company but covers a broad spectrum of activities; why as global business increases it…
The MD of Triclinium Clinical Development discusses how South Africa’s established First and Third World research opportunities and long-established GCP culture have made it a uniquely attractive country for clinical…
The country manager for BMS South Africa talks about the company’s first to market strategy, and how BMS has shifted the treatment paradigm for oncology in South Africa. Through our platform, we introduce the…
Iain Barton reveals how the acquisition of RTT Medical by IHS in 2013 has allowed Imperial to become the biggest pharma supply chain and general logistics services player on the African…
Peter Fuller provides us with an update on the integration of Covidien businesses, and explains how Medtronic is bringing innovation to South African patients and contributing to the improvement of the…
Adv. Leslie Sedibe, CEO of Proudly South African explains how the Proudly South African campaign aims to promote local products and services to ultimately address unemployment, and what his main…
The country president of Novartis South Africa reveals how Novartis has recently moved to new premises, demonstrating a clear commitment to continue investing in the country; why South Africa…
See our Cookie Privacy Policy Here